Okanvision Bio-B (01477) rose more than 6%. As of press release, it was up 5.83% to HK$6.35, with a turnover of HK$10.5044 million.
The Zhitong Finance App learned that Okanvision Bio-B (01477) rose more than 6%. As of press release, it had risen 5.83% to HK$6.35, with a turnover of HK$10.5044 million.
According to the news, recently, Oconvision announced that it has reached an agreement with Alcon. Oconvision will receive the rights of 8 Alcon ophthalmology products in China. According to the agreement, the company will fully obtain the rights to 7 mature products in the Chinese market, including Netearan, Tearane II, Bellan, Alkain, Recife, and Siran, as well as commercialization rights for AR-15512 (a novel topical drug candidate for dry eye) in China. Alcon, on the other hand, will hold 16.7% of Okanvision's shares (after issuance).
In the first half of this year, Okanvision achieved revenue of RMB 0.1676 billion, an increase of 61.6% year on year. Among them, revenue from sales of ophthalmic products reached 0.15 billion yuan, an increase of 78.1% year on year; adjusted net loss decreased by 20.0% year on year. CICC pointed out that the commercialization of the company is progressing smoothly, and the sales team continues to expand. As of June 2024, the company covered 10,970 hospital terminals, of which 1,652 were level-III hospitals, the number of commercial teams exceeded 250, and the national commercial network covered a full range. Among them, after Yu Shiying was officially included in the medical insurance catalogue at the end of 2023, she achieved nearly 2,000 injections in the first half of the year, which shows the company's ability to tap the commercial potential of the product.